Please login to the form below

Not currently logged in
Email:
Password:

Aplidin

This page shows the latest Aplidin news and features for those working in and with pharma, biotech and healthcare.

PharmaMar’s cancer drug has ‘potent preclinical efficacy’ against COVID-19

PharmaMar’s cancer drug has ‘potent preclinical efficacy’ against COVID-19

Aplidin inhibits the eEF1A protein, which is associated with the SARS-CoV-2 virus, and is approved in Australia as a multiple myeloma treatment. ... According to the recently published study, in vitro Aplidin showed antiviral potency against SARS-CoV-2

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...